Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 8/20 | 0.48 |
| ▸ | AKT2 | P31751 | 8/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15071103 | 0.86 | F2RL1 (0.56) | HPGDMAPK1F2RL1AKT1AKT2 | |
| SCHEMBL15071099 | 0.80 | F2RL1 (0.52) | HPGDF2RL1NPC1TSHRRAB9A | |
| SCHEMBL15071100 | 0.79 | F2RL1 (0.77) | HPGDMAPK1F2RL1AKT1AKT2 | |
| SCHEMBL15071143 | 0.77 | F2RL1 (0.74) | HPGDMAPK1F2RL1AKT1AKT2 | |
| SCHEMBL5322233 | 0.75 | CNR1 (0.58) | HPGDF2RL1AKT1AKT2CNR1 | |
| SCHEMBL5337926 | 0.75 | CNR1 (0.58) | HPGDF2RL1AKT1AKT2CNR1 | |
| SCHEMBL15071138 | 0.72 | F2RL1 (0.62) | HPGDMAPK1F2RL1AKT1AKT2 | |
| SCHEMBL3454812 | 0.71 | HPGD (0.96) | HPGDMAPK1NPC1TSHRRAB9A | |
| SCHEMBL3456729 | 0.71 | HPGD (0.96) | HPGDMAPK1NPC1TSHRRAB9A | |
| SCHEMBL22768015 | 0.71 | CYP1A2 (0.56) | HPGDMAPK1NPC1RAB9ACNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO.,LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO.,LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | F2RL1, F2R, FPR2 | HPGD 80/4885MAPK1 1566/4885F2RL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.